New Oral Form for ALS Drug

Area of Science:

• Neurology
• Pharmacology

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease.
• Edaravone is an existing treatment for ALS, previously available in intravenous form.

Purpose of the Study:

• To announce the FDA approval of an oral suspension of edaravone (Radicava ORS).
• To provide administration guidelines for the new oral suspension formulation of edaravone for ALS patients.

Main Methods:

• The study is based on the FDA approval of Radicava ORS.
• Administration instructions for oral or feeding tube delivery were detailed.

Main Results:

• Radicava ORS (edaravone oral suspension) has received FDA approval for ALS treatment.
• Specific administration protocols involving an empty stomach and feeding tube flushing are recommended.

Conclusions:

• The approval of Radicava ORS offers a new oral administration option for edaravone in ALS management.
• Proper administration is crucial for the efficacy and safety of edaravone treatment in ALS.